Peptide Schedule
Bromantane (Ladasten)Small moleculeNo amino acid sequence. Icon reflects category theme only.Bromantane (Ladasten) Dosage Calculator
Bromantane (N-(4-bromophenyl)adamantan-2-amine) is a synthetic actoprotector developed at the Russian Academy of Medical Sciences during the late 1980s.
25mcg · Daily
Summary: Add 0mL BAC water to your 100mg vial. Draw to < 0.1 units on a U-100 syringe for a 25mcg dose. This vial will last 0 doses.
Cycle Planner
Bromantane (Ladasten) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~11 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Bromantane (Ladasten) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 25mg | Daily |
| Moderate | 50mg | Daily |
| Aggressive | 100mg | Daily |
Note: Oral compound — no reconstitution needed. Taken as capsule, tablet, or sublingual powder. Not a peptide but commonly sold in the same market. Approved in Russia as Ladasten for neurasthenia; not FDA-approved. Banned by WADA as a stimulant. Cycle 4 weeks on, 2-4 weeks off.
About Bromantane (Ladasten)
Bromantane (N-(4-bromophenyl)adamantan-2-amine) is a synthetic actoprotector developed at the Russian Academy of Medical Sciences during the late 1980s. It's built on an adamantane scaffold — the same bicyclic carbon cage found in amantadine and memantine — with a brominated aniline group attached. This structural hybrid gives it a pharmacological profile that doesn't fit neatly into any single drug class: it's simultaneously a mild psychostimulant, an anxiolytic, and a physical performance enhancer. The compound first surfaced publicly after several athletes at the 1996 Atlanta Olympics tested positive for it. At that point, bromantane wasn't on the IOC's banned substance list, so those results were initially controversial. WADA later added it to the Prohibited List as a specified stimulant (category S6), where it remains today. What makes bromantane unusual is its mechanism. Unlike amphetamines or modafinil, it doesn't block dopamine reuptake or flood synapses with monoamines. Instead, it works through indirect genomic regulation — upregulating the expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD), the two rate-limiting enzymes in dopamine biosynthesis. A single dose can produce a 2- to 2.5-fold increase in TH expression in the hypothalamus within 1.5 to 2 hours. The downstream result is a gradual, sustained increase in dopamine synthesis rather than a sudden spike and crash. Bromantane's anxiolytic effects appear to operate through a separate pathway involving GABA-ergic mediation, which is why users often describe it as providing calm focus rather than the jittery stimulation typical of conventional stimulants. There's also evidence it increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in certain brain regions. Russia approved bromantane under the brand name Ladasten around 2009 for treating neurasthenia (chronic fatigue with cognitive complaints). A large multicenter trial involving 728 patients showed 90.8% improvement on the CGI-I scale at doses of 50-100 mg daily over 28 days, with adverse effects in only 3% of patients. That said, Western clinical data is extremely limited — there are no FDA-reviewed trials, no double-blind placebo-controlled studies published in English-language journals of the caliber you'd expect for a prescription drug, and most pharmacological data comes from Russian-language publications or preclinical animal work.